AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03589105
Drug: Ocrelizumab 300 mg
RxNorm normalized name: ocrelizumab 300 MG in 10 ML Injection
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two doses of 300 mg infusion administered 14 days apart.
Trial: NCT03589105
Drug: Ocrelizumab 600 mg
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single does of 600 mg infusion administered 24 weeks after the initial dose.
Trial: NCT00063583
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
Trial: NCT00646841
Drug: Doxazosin gastrointestinal therapeutic system (GITS)
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
Trial: NCT01277341
Drug: Bepotastine Besilate Nasal Spray 2% Twice a day
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nasal spray
Trial: NCT01277341
Drug: Bepotastine Besilate Nasal Spray 3% Twice a day
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nasal spray
Trial: NCT01277341
Drug: Bepotastine Besilate Nasal Spray 4% Twice a day
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nasal spray
Trial: NCT04729491
Drug: Dutasteride 0.5 mg
RxNorm normalized name: dutasteride 0.5 MG
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
Trial: NCT04729491
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg twice daily for 06 days
Trial: NCT02671942
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02860806
Drug: JNJ-63623872
RxNorm normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
Trial: NCT03013010
Drug: Tegafur-Gimeracil-Oteracil Potassium
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
Trial: NCT03013010
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Trial: NCT03776136
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally once a day during each 21-day cycle.
Trial: NCT00613951
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
Trial: NCT00613951
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treat-to-target dose titration scheme, injection s.c., twice daily
Trial: NCT00613951
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 1500-2000 mg/daily
Trial: NCT01839734
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg by mouth (PO) once-daily
Trial: NCT00655980
Drug: Nitrous oxide and placebo
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01953796
Drug: clomiphene
RxNorm normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
Trial: NCT03838068
Drug: Local Anesthetics Procaine
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
Trial: NCT01606761
Drug: Sirukumab
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
Trial: NCT01606761
Drug: Sirukumab
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
Trial: NCT01606761
Drug: Sirukumab
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
Trial: NCT02497157
Drug: Oxaliplatin (L-OHP)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02497157
Drug: Irinotecan hydrochloride hydrate (CPT-11)
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02497157
Drug: Bevacizumab (Bmab)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03150108
Drug: rhPTH(1-84)
RxNorm normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mcg rhPTH(1-84) SC injection
Trial: NCT03150108
Drug: rhPTH(1-84)
RxNorm normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mcg rhPTH(1-84) SC injection
Trial: NCT03150108
Drug: rhPTH(1-84)
RxNorm normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mcg rhPTH(1-84) SC injection
Trial: NCT00993421
Drug: Sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given daily, orally for 24 weeks
Trial: NCT00993421
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
Trial: NCT00651508
Drug: KOS-1584
RxNorm normalized name: KOS-1584
DrugBank: KOS-1584 (DB05903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
Trial: NCT00993421
Drug: Placebo sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given daily, orally for 24 weeks
Trial: NCT00993421
Drug: Placebo Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
Trial: NCT00145249
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
Trial: NCT00145249
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
Trial: NCT00135837
Drug: Verteporfin for injection
RxNorm normalized name: Verteporfin for Injection
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00005096
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02340988
Drug: Single-Dose IV Oritavancin Diphosphate and Warfarin
RxNorm normalized name: Oritavancin Diphosphate
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
Trial: NCT02340988
Drug: Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
RxNorm normalized name: Oritavancin Diphosphate
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
Trial: NCT01015482
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam Infusion
Trial: NCT05737173
Drug: Leukocyte-rich platelet-rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular knee injection
Trial: NCT05737173
Drug: Leukocyte-poor platelet-rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular knee injection
Trial: NCT03690869
Drug: cemiplimab (monotherapy)
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To be administered intravenously as monotherapy in Phase 1
Trial: NCT03690869
Drug: cemiplimab (maintenance)
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To be administered intravenously in combination with radiation and then used as maintenance therapy
Trial: NCT01304589
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
Trial: NCT00154882
Drug: Paclitaxel (Phyxol) , Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02681952
Drug: Renamezin capsule
RxNorm normalized name: Cefamezin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02681952
Drug: Kremezin granule
RxNorm normalized name: METHYL SALICYLATE 31 g in 100 g / MENTHOL, UNSPECIFIED FORM 11 g in 100 g TOPICAL CREAM [FREEZIN COLD TOAST]
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00575952
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or IP
Trial: NCT00575952
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or IP
Trial: NCT04274608
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intragastric injection of Botulinum toxin type A
Trial: NCT02478294
Drug: Warfarin or Novel Oral Anticoagulants
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this group, patients receive warfarin or novel oral anticoagulants
Trial: NCT02489500
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1
Trial: NCT02489500
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0
Trial: NCT02489500
Drug: Neupogen
RxNorm normalized name: Neupogen
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
Trial: NCT01672775
Drug: AGS-16C3F
RxNorm normalized name: AGS-16C3F
DrugBank: AGS-16C3F (DB17551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) infusion
Trial: NCT05531994
Drug: Montelukast sodium oral thin films with water (T)
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
Trial: NCT05531994
Drug: Montelukast sodium chewable tablets with water (R)
RxNorm normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
Trial: NCT00293735
Drug: labetalol (seizure prevention)
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours
Trial: NCT00293735
Drug: MgSO4 (seizure prevention)
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
Trial: NCT00648193
Drug: Paroxetine hydrochloride 40 mg tablet
RxNorm normalized name: paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fasting
Trial: NCT00006054
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006054
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006054
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006054
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006054
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006054
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02467647
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02467647
Drug: HLJDT
RxNorm normalized name: Huperzine A, Ligustrazine, Jasminoidin, Danggui, Tetramethylpyrazine
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00208312
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg, bolus intravenous injection
Trial: NCT03553433
Drug: Apremilast 30mg
RxNorm normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-psoriatic drug
Trial: NCT00796601
Drug: Esreboxetine
RxNorm normalized name: Esreboxetine
DrugBank: Esreboxetine (DB12395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
Trial: NCT00389740
Drug: Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03745196
Drug: PC945
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study drug under investigation
Trial: NCT02602938
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take aspirin (100mg) orally once a day for 2 months
Trial: NCT03414008
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02408055
Drug: TA-8995
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01889966
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Sildenafil 3 x 20 mg for 90 days
Trial: NCT01321502
Drug: famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg tablet
Trial: NCT03386656
Drug: Amchafibrin
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
Trial: NCT00975195
Drug: tiotropium inhalation
RxNorm normalized name: Tiotropium Inhalation Spray
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975195
Drug: salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00975195
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00975195
Drug: placebo matched for fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04378920
Drug: LEAF-4L6715
RxNorm normalized name: Belladonna Leaf
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEAF-4L6715
Trial: NCT02623036
Drug: Equivalent dose enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronotherapy with enalapril.
Trial: NCT02623036
Drug: Equivalent dose lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronotherapy with lisinopril
Trial: NCT00099359
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
Trial: NCT00099359
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams
Trial: NCT00252642
Drug: Peginterferon Alpha-2a
RxNorm normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00099359
Drug: Epivir (3TC)
RxNorm normalized name: lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams
Trial: NCT00099359
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
Trial: NCT00176670
Drug: midazolam or GameBoy or parental presence
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01485926
Drug: Docetaxel, Carboplatin and Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
Trial: NCT01485926
Drug: Docetaxel, Carboplatin, Trastuzumab and Lapatinib
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
Trial: NCT00717366
Drug: Methoxy Polyethylene Glycol-Epoetin Beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered IV, every 4 weeks.
Trial: NCT01546389
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)